Taken together, our study not only confirms prior observational findings on SGLT2 inhibitors but also extends mechanistic evidence to the inflammatory and fibrotic pathways in NAFLD [40]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.